In vivo efficacy of platelet-delivered, high specific activity factor VIII variants
about
MicroRNAs in platelet production and activationAssessment of Venous Thrombosis in Animal ModelsThe gene therapy journey for hemophilia: are we there yet?The C-terminal CGHC motif of protein disulfide isomerase supports thrombosis.Gene therapy for hemophiliaLessons Learned from Animal Models of Inherited Bleeding Disorders.The disulfide isomerase ERp57 is required for fibrin deposition in vivo.Apoptotic effects of platelet factor VIII on megakaryopoiesis: implications for a modified human FVIII for platelet-based gene therapy.Role of bone marrow transplantation for correcting hemophilia A in mice.α-Defensins Induce a Post-translational Modification of Low Density Lipoprotein (LDL) That Promotes Atherosclerosis at Normal Levels of Plasma CholesterolThe immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunityEngineering Factor Viii for Hemophilia Gene Therapy.Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice.Ectopic platelet-delivered factor (F) VIII for the treatment of Hemophilia A: Plasma and platelet FVIII, is it all the same?Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.Factor VIII inhibitors: a 50-year perspective.Gene therapy for haemophilia: a long and winding road.Blood Clotting Factor VIII: From Evolution to Therapy.Obstacles and future of gene therapy for hemophilia.Platelet-delivered therapeutics.Gene therapy for immune tolerance induction in hemophilia with inhibitors.Targeting expression to megakaryocytes and platelets by lineage-specific lentiviral vectors.Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.The search for the origin of factor VIII synthesis and its impact on therapeutic strategies for hemophilia A.Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.Platelet-Targeted Gene Therapy for Hemophilia.Enhanced factor VIIIa stability of A2 domain interface variants results from an increased apparent affinity for the A2 subunit. Results from an increased apparent affinity for the A2 subunit.
P2860
Q24622537-E8C25FD2-E31E-4D97-A827-A36B69BC5501Q26774967-90A6953D-FC39-44B3-94E9-68F30DBC9B6AQ26823818-2F29CB52-51B4-4A27-ADCF-6A43EA40CB8CQ27332350-00033A88-4C06-4362-B326-25F03CCD757EQ28081911-4DF31098-550E-4869-A6C3-A741A1488A7DQ30409863-A62BB0C8-842D-4071-B769-7B655AC5C265Q35231637-80D102D8-7A6F-412B-8E2C-4F1242E07EACQ35306206-2D0CF087-E38D-4426-849D-23B7DB4E2314Q36015228-69663D31-629E-4692-8B6C-61CD51CE2023Q36548363-A943836B-06AE-443C-AD84-837DF616041AQ36675079-DE84CFB3-1008-4FFB-8846-DD64217C9E82Q36737263-8E22BDD7-B811-44DE-A777-DA2D01764FE5Q36873312-6D27FDAC-2328-45DC-923C-A62A76E46584Q37292357-D7E1B84D-8EE0-4D80-8ACC-730BDF423453Q37366619-61C45DF6-5E17-4F32-A626-0D4E7ED9B735Q37489033-B45D8663-3CDC-47B4-B03C-807FC035F2D4Q37876956-359136A1-6C3C-4D8D-9134-B92708F7A483Q37903924-6CFF4CAF-5047-4796-B676-1F1B3173AF49Q38118763-257F7A09-3F03-4AAB-9C64-62247545B755Q38529941-ADE15324-0298-4D6C-A359-438EC1FCF58DQ38543281-9938A081-B41F-4334-B515-CD88D57E759BQ38803022-A4BC7461-56B5-40B0-A3DB-7A99C1535C69Q40435211-EFA8E2EE-9C83-462C-8B31-ED877161253EQ42209182-AC1916F5-9EB7-4F1C-B5A4-36F2D7EF76C3Q42384645-23324E61-A8C5-494F-A276-9C4C5167AFD7Q45857189-BFD1463F-05CE-401E-9F53-39D930A77CE0Q54975244-45985A05-35BE-42D2-A37D-81B950EF48E3Q55013009-5A194AD5-CF35-44C6-8FAD-E93F6B7F527F
P2860
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants
@ast
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants
@en
type
label
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants
@ast
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants
@en
prefLabel
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants
@ast
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants
@en
P2093
P2860
P1433
P1476
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants
@en
P2093
Cheng Wang
Hongzhi Z Miao
Jamie Gewirtz
Jessica D Hirsch
Michael A Thornton
Mortimer Poncz
Randal J Kaufman
Rodney M Camire
Steven W Pipe
P2860
P304
P356
10.1182/BLOOD-2010-06-293308
P407
P577
2010-09-17T00:00:00Z